Back to top

Image: Bigstock

Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today

Read MoreHide Full Article

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.

Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.

What if you'd invested in Thermo Fisher Scientific (TMO - Free Report) ten years ago? It may not have been easy to hold on to TMO for all that time, but if you did, how much would your investment be worth today?

Thermo Fisher Scientific's Business In-Depth

With that in mind, let's take a look at Thermo Fisher Scientific's main business drivers.

Headquartered in Waltham, MA, Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In November 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb. 3, 2014, Thermo Fisher acquired Life Technologies Corporation.

In terms of end market served, there are four divisions-- pharmaceutical and biotech, academic and government, industrial and applied, and healthcare and diagnostics.

Following the acquisition, the new reporting segments are:

The Life Sciences Solutions segment, representing 23.3% of total revenues in 2025, was added post the acquisition of Life Technologies. It incorporates the majority of the former Life Technologies and Thermo Fisher’s Biosciences businesses. In 2025, this business registered growth of 7.7% from the 2024 level.

In September 2025, the company completed the acquisition of Solventum’s Purification & Filtration business. In July 2024, Thermo Fisher acquired Olink, a provider of next-generation proteomics solutions.

The Analytical Instruments segment, which represented 17% of total revenues in 2025, has been renamed to reflect the transfer of the bioprocess production business to the newly formed Life Sciences Solutions Segment. In 2025, this business registered growth of 1.2% from the 2024 level.

The Specialty Diagnostics (SD) segment represents 10.5% of total revenues, formed after the acquisition of Phadia, serves customers in healthcare and clinical laboratories with a portfolio of diagnostic test kits, reagents and instruments used to increase the speed and accuracy of diagnoses to improve patient care. In 2025, this business registered growth of 3.6% from the 2024 level.

Laboratory Products and Biopharma Services,  represents 55.8% of total revenues. It has been renamed to reflect the inclusion of the PPD acquisition. PPD has been referred to as a clinical research business within this segment. In 2025, this business registered growth of 3.6% from the 2024 level.

Bottom Line

Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Thermo Fisher Scientific, ten years ago, you're likely feeling pretty good about your investment today.

According to our calculations, a $1000 investment made in September 2016 would be worth $4,302.87, or a gain of 330.29%, as of September 25, 2026, and this return excludes dividends but includes price increases.

In comparison, the S&P 500's gained 255.90% and the price of gold went up 207.04% over the same time frame.

Analysts are forecasting more upside for TMO too.

Thermo Fisher is gaining from improving customer activity across all end markets, continued share gains and disciplined execution of its growth strategy. Pharma and biotech demand is advancing, led by bioproduction, clinical research and the research and safety channel. Clario and the filtration and separation business are bolstering the company's capabilities and supporting revenue synergies. New products, AI-enabled workflows and expanded customer collaboration centers reinforce its competitive position. Management raised its 2026 revenue and adjusted EPS outlook after better-than-expected second-quarter results. The Zacks Consensus Estimate projects 2026 EPS of $25.12 on revenues of $47.80 billion. Still, macroeconomic uncertainty, currency volatility, acquisition-related leverage and intense competition remain key risks.

The stock is up 7.56% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 3 higher, for fiscal 2026. The consensus estimate has moved up as well.

Published in